AKTS
Aktis Oncology·NASDAQ
--
--(--)
--
--(--)
8.46 / 10
Outperform
Evaluation yields 8.5/10, reflecting superior financial health. Key positives: Current assets turnover ratio and Fixed assets turnover ratio, offset by weaknesses in Gross profit margin (%). This configuration appears exceptionally strong.
Analysis Checks(3/4)
Inventory turnover ratio
Value24.94
Score2/3
Weight-190.40%
1M Return-2.37%
Value24.94
Score2/3
Weight-190.40%
1M Return-2.37%
Current assets turnover ratio
Value0.00
Score2/3
Weight147.47%
1M Return1.75%
Value0.00
Score2/3
Weight147.47%
1M Return1.75%
Gross profit margin (%)
Value100.00
Score1/3
Weight17.13%
1M Return0.22%
Value100.00
Score1/3
Weight17.13%
1M Return0.22%
Fixed assets turnover ratio
Value0.10
Score3/3
Weight125.80%
1M Return1.53%
Value0.10
Score3/3
Weight125.80%
1M Return1.53%
Inventory turnover ratio
Value24.94
Score2/3
Weight-190.40%
1M Return-2.37%
Value24.94
Score2/3
Weight-190.40%
1M Return-2.37%
Gross profit margin (%)
Value100.00
Score1/3
Weight17.13%
1M Return0.22%
Value100.00
Score1/3
Weight17.13%
1M Return0.22%
Current assets turnover ratio
Value0.00
Score2/3
Weight147.47%
1M Return1.75%
Value0.00
Score2/3
Weight147.47%
1M Return1.75%
Fixed assets turnover ratio
Value0.10
Score3/3
Weight125.80%
1M Return1.53%
Value0.10
Score3/3
Weight125.80%
1M Return1.53%
Is AKTS undervalued or overvalued?
- AKTS scores 8.46/10 on fundamentals and holds a Discounted valuation at present. Backed by its -21.76% ROE, -1090.81% net margin, -16.44 P/E ratio, 4.96 P/B ratio, and 9.35% earnings growth, these metrics solidify its Outperform investment rating.
